

**UNITED STATES
CRITICAL LIMB ISCHEMIA BY RUTHERFORD CATEGORY
PREVALENCE AND MARKETS
IN PATIENTS AND LIMBS**

Mary L. Yost
THE SAGE GROUP
404-520-6652

THE SAGE GROUP, LLC
23 Ridge Rd
Beaufort, SC

Copyright Pending
December 2017

All rights reserved, including the right of reproduction
in whole or in part in any form.

Table of Contents

PREVALENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA	5
CRITICAL LIMB ISCHEMIA ESTIMATES BY RUTHERFORD CATEGORY... 5	5
TREATMENT PATHWAY ACCORDING TO RUTHERFORD CATEGORY	6
PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA PREVALENCE—HIGH SERIES.....	7
Patient and Limb Prevalence 2015-2030	7
CRITICAL LIMB ISCHEMIA PREVALENCE BY RUTHERFORD CATEGORY—HIGH SERIES	8
Patient Prevalence According to Rutherford Category.....	8
Prevalence in Number of Limbs According to Rutherford Category	8
RUTHERFORD CATEGORY 4 PREVALENCE ACCORDING TO TREATMENT PATHWAY—HIGH SERIES.....	9
Prevalence of Patients in Each Treatment Pathway.....	9
Prevalence of Limbs in Each Treatment Pathway	9
RUTHERFORD CATEGORY 4 MARKET BY TREATMENT PATHWAY—HIGH SERIES	10
Patient Market in Each Treatment Pathway.....	10
Limb Market in Each Treatment Pathway	10
RUTHERFORD CATEGORY 5 PREVALENCE ACCORDING TO TREATMENT PATHWAY—HIGH SERIES.....	11
Prevalence of Patients in Each Treatment Pathway.....	11
Prevalence of Limbs in Each Treatment Pathway	11
RUTHERFORD CATEGORY 5 MARKET BY TREATMENT PATHWAY—HIGH SERIES	12
Patient Market in Each Treatment Pathway.....	12
Limb Market in Each Treatment Pathway	12
RUTHERFORD CATEGORY 6 PREVALENCE ACCORDING TO TREATMENT PATHWAY—HIGH SERIES.....	13
Prevalence of Patients in Each Treatment Pathway.....	13
Prevalence of Limbs in Each Treatment Pathway	13
RUTHERFORD CATEGORY 6 MARKET BY TREATMENT PATHWAY—HIGH SERIES	14
Patient Market in Each Treatment Pathway.....	14
Limb Market in Each Treatment Pathway	14
CRITICAL LIMB ISCHEMIA PREVALENCE—LOW SERIES.....	15
Patient and Limb Prevalence 2015-2030	15
CRITICAL LIMB ISCHEMIA PREVALENCE BY RUTHERFORD CATEGORY—LOW SERIES	16
Patient Prevalence According to Rutherford Category.....	16
Prevalence in Number of Limbs According to Rutherford Category	16
RUTHERFORD CATEGORY 4 PREVALENCE ACCORDING TO TREATMENT PATHWAY—LOW SERIES.....	17
Prevalence of Patients in Each Treatment Pathway.....	17

Prevalence of Limbs in Each Treatment Pathway	17
RUTHERFORD CATEGORY 4 MARKET BY TREATMENT PATHWAY—LOW SERIES	18
Patient Market in Each Treatment Pathway.....	18
Limb Market in Each Treatment Pathway	18
RUTHERFORD CATEGORY 5 PREVALENCE ACCORDING TO TREATMENT PATHWAY—LOW SERIES.....	19
Prevalence of Patients in Each Treatment Pathway.....	19
Prevalence of Limbs in Each Treatment Pathway	19
RUTHERFORD CATEGORY 5 MARKET BY TREATMENT PATHWAY—LOW SERIES	20
Patient Market in Each Treatment Pathway.....	20
Limb Market in Each Treatment Pathway	20
RUTHERFORD CATEGORY 6 PREVALENCE ACCORDING TO TREATMENT PATHWAY—LOW SERIES.....	21
Prevalence of Patients in Each Treatment Pathway.....	21
Prevalence of Limbs in Each Treatment Pathway	21
RUTHERFORD CATEGORY 6 MARKET BY TREATMENT PATHWAY—LOW SERIES	22
Patient Market in Each Treatment Pathway.....	22
Limb Market in Each Treatment Pathway	22
APPENDIX A: HCUP METHOD	23
Healthcare Cost and Utilization Project.....	23
HCUP-Weighted Method.....	23
HCUP Patient Data for 1998, 2007 and 2008.....	24
REFERENCES.....	26
INDEX OF TABLES	27
CONTACT INFORMATION.....	30

CONTACT INFORMATION

Research

Mary L. Yost
President and Senior Analyst
Telephone (404) 520-6652
yost@thesagegroup.us

Marketing

Harrington Witherspoon
Senior Vice President
Marketing
Telephone (404) 816-0746
witherspoon@thesagegroup.us